SphingoTec
SphingoTec develops and markets innovative in vitro diagnostics solutions for novel and proprietary blood-based protein biomarkers. Their aspiration is to translate scientific advancements into routine clinical practice effectively. They develop biomarkers addressing diagnostically underserved critical care conditions such as acute kidney injury, sepsis and acute heart failure. First and foremost, their portfolio of tests supports better management of critically ill patients, where fast and reliable information is of the essence in taking treatment decisions.
Latest SphingoTec Content
Product News
Beckman Coulter and SphingoTec Partner To Improve Kidney Health Assessment in Critical Care
Diagnostic company SphingoTec GmbH (“SphingoTec”) announced a new partnership with Beckman Coulter Diagnostics Inc. (“Beckman Coulter”).
Article
Using Novel Biomarkers To Identify the Risk of Cardiovascular Disease
This article explores the importance of early risk prediction in preventing cardiovascular disease (CVD), the role of biomarkers in this prediction and nutritional habits to reduce the risk of CVD.
Article
Glomerular Filtration Rate Is the True Gold Standard of Kidney Function
This article discusses acute kidney injury, calculating the glomerular filtration rate and the need for a reliable functional kidney biomarker.
Advertisement
